{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
AVITA Medical, Inc.
AVITA Medical Hits 52-Week Low at $3.37 Amidst Significant Decline
AVITA Medical, Inc. has reached a new 52-week low, reflecting a challenging year with a significant decline from its previous high. The company, with a market capitalization of USD 112 million, faces concerns over its financial health, including negative book value and poor debt management metrics.
Is AVITA Medical, Inc. technically bullish or bearish?
As of August 19, 2025, AVITA Medical, Inc. is in a bearish trend with moderate strength, indicated by a bearish monthly MACD and poor performance against the S&P 500, showing a year-to-date return of -56.72% compared to the S&P 500's 12.22%.
Is AVITA Medical, Inc. overvalued or undervalued?
As of May 13, 2021, AVITA Medical, Inc. is considered risky and overvalued, with poor financial metrics and a year-to-date return of -59.84%, significantly underperforming the S&P 500's 2.44%.
Is AVITA Medical, Inc. technically bullish or bearish?
As of May 9, 2025, AVITA Medical, Inc. shows a strong bearish outlook, with bearish signals from MACD, Bollinger Bands, moving averages, and KST across both weekly and monthly time frames.
Who are in the management team of AVITA Medical, Inc.?
As of March 2022, the management team of AVITA Medical, Inc. includes Mr. Lou Panaccio (Independent Non-Executive Chairman), Dr. Michael Perry (CEO and Executive Director), and Independent Non-Executive Directors Mr. Jeremy Cook, Prof. Suzanne Crowe, and Mr. Louis Drapeau. They oversee the company's strategic direction and operations.
What does AVITA Medical, Inc. do?
AVITA Medical, Inc. is a regenerative medicine company focused on developing treatments for burn injuries, chronic wounds, and dermatological conditions. As of March 2025, it reported net sales of $19 million and a net loss of $14 million, with a market cap of $137.72 million.
How big is AVITA Medical, Inc.?
As of Jun 18, AVITA Medical, Inc. has a market capitalization of 137.72 million and reported net sales of 71.67 million, with a net profit of -57.05 million for the latest four quarters. Shareholder's funds are 4.50 million, and total assets amount to 79.71 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
